PHYRAGO Drug Patent Profile
✉ Email this page to a colleague
When do Phyrago patents expire, and when can generic versions of Phyrago launch?
Phyrago is a drug marketed by Handa Therap and is included in one NDA. There are six patents protecting this drug.
The generic ingredient in PHYRAGO is dasatinib. Sixteen suppliers are listed for this compound. Additional details are available on the dasatinib profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phyrago
A generic version of PHYRAGO was approved as dasatinib by APOTEX on June 10th, 2016.
US Patents and Regulatory Information for PHYRAGO
PHYRAGO is protected by twenty US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-002 | Dec 5, 2023 | RX | Yes | No | 11,298,356 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-003 | Dec 5, 2023 | RX | Yes | No | 11,324,745 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-003 | Dec 5, 2023 | RX | Yes | No | 12,433,891 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-003 | Dec 5, 2023 | RX | Yes | No | 11,298,356 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PHYRAGO
See the table below for patents covering PHYRAGO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2021210974 | Amorphous solid dispersions of dasatinib and uses thereof | ⤷ Start Trial |
| Canada | 3168667 | DISPERSIONS SOLIDES AMORPHES DE DASATINIB ET LEURS UTILISATIONS (AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF) | ⤷ Start Trial |
| European Patent Office | 4093379 | DISPERSIONS SOLIDES AMORPHES DE DASATINIB ET LEURS UTILISATIONS (AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF) | ⤷ Start Trial |
| European Patent Office | 4714503 | DISPERSIONS SOLIDES AMORPHES DE DASATINIB ET LEURS UTILISATIONS (AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PHYRAGO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1169038 | C300567 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 .... 009 20061120 |
| 1169038 | 122013000012 | Germany | ⤷ Start Trial | PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH GEEIGNETE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-009 EU/1/06/363/010-011 EU/1/06/363/012-015 20061120 |
| 1169038 | 132013902119320 | Italy | ⤷ Start Trial | PRODUCT NAME: DASATINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(SPRYCEL); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/06/363/001 A EU/I/06/363/015, 20061120 |
| 1169038 | 300567 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch